128 results on '"Sheldon, R. S."'
Search Results
2. Syncope recurrence and long-term heart rate variability after cardioneuroablation for vasovagal syncope: a systematic review and meta-analysis
3. Distinguishing Syncope From Seizures: How Useful is the Clinical History?
4. Secondary Prevention of Sudden Death in Post-Infarction Patients: When is ICD Implantation Really Cost-Effective?
5. Pacing for Vasovagal Syncope: Real Efficacy or Placebo Effect?
6. Vasovagal Syncope: To Pace or not to Pace?
7. What Do We Know Today About the Outcome of Vasovagal Syncope?
8. S.W. Flower & Company [catalog].
9. Vasovagal Syncope: To Pace or not to Pace?
10. The face of postural tachycardia syndrome – insights from a large cross‐sectional online community‐based survey
11. β-Blockers for Prevention of Vasovagal Syncope: Who Benefits from Treatment?
12. Syncope recurrence and mortality: a systematic review
13. Empiric pacemaker compared with a monitoring strategy in patients with syncope and bifascicular conduction block--rationale and design of the Syncope: Pacing or Recording in ThE Later Years (SPRITELY) study
14. Impact of atrial antitachycardia pacing and atrial pace prevention therapies on atrial fibrillation burden over long-term follow-up
15. Beneficial effects of statin therapy for prevention of atrial fibrillation following DDDR pacemaker implantation
16. Decrease in density of INa is in the common final pathway to heart block in murine hearts overexpressing calcineurin
17. Evaluation of the bias in using the time to the first event when the inter-event intervals have a Weibull distribution
18. Electrocardiographic correlates of spontaneous termination of ventricular tachycardia in patients with coronary artery disease.
19. Upregulation of the rat cardiac sodium channel by in vivo treatment with a class I antiarrhythmic drug.
20. Decrease in density of INa is in the common final pathway to heart block in murine hearts overexpressing calcineurin.
21. Quinidine/Quinine: Stereospecific Electrophysiologic and Antiarrhythmic Effects in a Canine Model of Ventricular Tachycardia
22. Mexiletine-quinidine in isolated hearts: an interaction involving the sodium channel.
23. RELATION OF ENAMELING IRON PREPARATION AND ACCESSORY CONDITIONS TO COPPERHEAD-TYPE DEFECTS*.
24. Ring and link requirements for tocainide binding to the class I antiarrhythmic drug receptor on rat cardiac myocytes.
25. Binding of [3H]batrachotoxinin A benzoate to specific sites on rat cardiac sodium channels.
26. Aminoalkyl structural requirements for interaction of lidocaine with the class I antiarrhythmic drug receptor on rat cardiac myocytes.
27. Class I antiarrhythmic drug receptor: biochemical evidence for state-dependent interaction with quinidine and lidocaine.
28. Determinants of stereospecific binding of type I antiarrhythmic drugs to cardiac sodium channels.
29. Stereospecific interaction of tocainide with the cardiac sodium channel.
30. Class I antiarrhythmic drugs: allosteric inhibitors of [3H] batrachotoxinin binding to rat cardiac sodium channels.
31. Amiodarone: biochemical evidence for binding to a receptor for class I drugs associated with the rat cardiac sodium channel.
32. Antiarrhythmic drugs and the cardiac sodium channel: current models.
33. Tetrodotoxin: sodium channel specific anti-arrhythmic activity
34. A receptor for type I antiarrhythmic drugs associated with rat cardiac sodium channels.
35. Comment: Syncope and Sudden Death in Hypertrophic Cardiomyopathy
36. A Prospective Randomized Comparison of Autodecremental Pacing to Burst Pacing in Device Therapy for Chronic Ventricular Tachycardia Secondary to Coronary Artery Disease
37. Risks of Developing Supraventricular and Ventricular Tachyarrhythmias After Implantation of a Cardioverter-Defibrillator, and Timing the Activation of Arrhythmia Termination Therapies
38. Cost-utility analysis of pacemakers for the treatment of vasovagal syncope.
39. Telemetry-documented, pace-terminable ventricular tachycardia in patients with ventricular fibrillation.
40. Decrease in density of INa is in the common final pathway to heart block in murine hearts overexpressing calcineurin.
41. Overexpression of calcineurin in mouse causes sudden cardiac death associated with decreased density of K+ channels.
42. The implantable cardioverter-defibrillator. Current indications and controversies.
43. Beta-blockers in syncope: the jury is still out.
44. The implantable cardioverter-defibrillator: does everybody need one?
45. Do baseline characteristics accurately discriminate between patients likely versus unlikely to benefit from implantable defibrillator therapy? Evaluation of the Canadian implantable defibrillator study implantable cardioverter defibrillatory efficacy score in the antiarrhythmics versus implantable defibrillators trial.
46. Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy.
47. Conduction time oscillations precede the spontaneous termination of human atrioventricular reciprocating tachycardia.
48. Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone.
49. Large-magnitude, transient, bradycardic events in rabbits.
50. Information scaling properties of heart rate variability.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.